M2 Archive: Preview


You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.


Japan's regulator approves Grifols' Lynspad™ [alpha-1 proteinase inhibitor] for the treatment of alpha-1 antitrypsin deficiency

Barcelona, Spain, and Tokyo - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 100-year track record of contributing to the health and well-being of people around the world, and OrphanPacific, Inc., which provides drugs...  


If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search